{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T23:54:44Z","timestamp":1784591684671,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Breast cancer is the leading cause of cancer-related deaths among women globally, including Brazil. This study assesses neoadjuvant treatment patterns, the impact of new therapies, and factors determining palliative care for patients who failed initial treatments. A historical cohort study using secondary data from DATASUS (2008\u20132017) focused on women aged 18\u201390 with stages II and III breast cancer who received neoadjuvant treatment. Data on chemotherapy, hormonal therapy, and anti-HER2 treatment were analyzed. The Palliative Treatment Rate (PTR) was calculated by cross-referencing neoadjuvant treatment records with subsequent palliative care records, indicating cases where the initial curative intent was not achieved. The study included 71,181 patients, with a mean age of 51.5 years. Most were diagnosed at Stage III (85%). Anti-HER2 therapy was introduced in 2013, with 10.5% receiving it. The 5-year PTR decreased from 44% (2008\u20132012) to 36% (2013\u20132017). The combination of chemotherapy, endocrine therapy, and anti-HER2 therapy had the lowest PTR. Logistic regression identified younger age, higher histological grade, Stage III disease, and compromised lymph nodes as factors increasing the likelihood of needing palliative care, while HER2 positivity and hormonal therapy reduced it. Regional disparities were observed, with patients from the Southeast more likely to receive palliative care. Early diagnosis and access to anti-HER2 therapy significantly reduce palliative care needs. Socio-economic and regional disparities in treatment highlight the need for equitable access to diagnostic tools and therapies to improve survival outcomes in Brazil\u2019s public healthcare system.<\/jats:p>","DOI":"10.1038\/s41598-025-06113-7","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:15:12Z","timestamp":1751382912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Incidence of palliative treatment among breast cancer patients undergoing neoadjuvant therapy: an analysis of the Brazilian public health system"],"prefix":"10.1038","volume":"15","author":[{"given":"Ana Maria Fantini","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breno","family":"Piva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Ant\u00f4nio Prado","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"6113_CR1","unstructured":"Inca Instituto Nacional De C\u00e2ncer Jos\u00e9 Alencar Gomes Da Silva. Estimativa 2023. Incid\u00eancia Do C\u00e2ncer No Brasil (INCA, 2019)."},{"key":"6113_CR2","unstructured":"WHO, World Health Organization. International Agency for Research on Cancer. Globocan."},{"key":"6113_CR3","unstructured":"Inca Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva. Atlas da Mortalidade. Rio de janeiro: INCA. Acesso em 22 de mar\u00e7o de 2021."},{"issue":"3","key":"6113_CR4","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"6113_CR5","doi-asserted-by":"crossref","unstructured":"Tiezzi, D. Jun. C\u00e2ncer de mama: um futuro desafio para o sistema de sa\u00fade nos pa\u00edses em desenvolvimento. Editorial  Rev. Bras. Ginecol. Obstet. 32 (6)  (2010).","DOI":"10.1590\/S0100-72032010001200001"},{"key":"6113_CR6","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1038\/s41598-021-82047-0","volume":"11","author":"NPD De Oliveira","year":"2021","unstructured":"De Oliveira, N. P. D. et al. A multilevel assessment of the social determinants associated with the late stage diagnosis of breast cancer. Sci. Rep. 11, 2712 (2021).","journal-title":"Sci. Rep."},{"key":"6113_CR7","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1245\/s10434-018-6486-6","volume":"25","author":"AE Giuliano","year":"2018","unstructured":"Giuliano, A. E., Edge, S. B. & Hortobagyi, G. N. Eighth edition of the AJCC Cancer staging manual: breast Cancer. Ann. Surg. Oncol. 25, 1783\u20131785 (2018).","journal-title":"Ann. Surg. Oncol."},{"key":"6113_CR8","first-page":"43","volume":"7","author":"AP Cecilio","year":"2015","unstructured":"Cecilio, A. P. et al. Breast cancer in brazil: epidemiology and treatment challenges. Breast Cancer (Dove Med. Press). 7, 43\u201349 (2015).","journal-title":"Breast Cancer (Dove Med. Press)"},{"key":"6113_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.breast.2019.01.008","volume":"44","author":"SD Simon","year":"2019","unstructured":"Simon, S. D. et al. Characteristics and prognosis of stage I-III breast cancer subtypes in brazil: the AMAZONA retrospective cohort study. Breast 44, 113\u2013119 (2019). j.breast.2019.01.008. Epub 2019 Feb 2.","journal-title":"Breast"},{"key":"6113_CR10","unstructured":"Inca Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva. Atlas da Mortalidade. Rio de janeiro: INCA. Acesso em 22 de mar\u00e7o de 2024 (2022)."},{"key":"6113_CR11","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12885-019-5499-2","volume":"19","author":"J Klein","year":"2019","unstructured":"Klein, J. et al. Locally advanced breast cancer treated with neoadjunvant chemotherapy and adjuvant radiotherapy: a retrospective cohort analysis. BMC Cancer. 19, 306 (2019).","journal-title":"BMC Cancer"},{"issue":"5","key":"6113_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1093\/oncolo\/oyac050","volume":"27","author":"MN Shafaee","year":"2022","unstructured":"Shafaee, M. N. et al. Breast Cancer treatment delay in SafetyNet health systems, Houston versus Southeast Brazil. Oncologist 27 (5), 344\u2013351. https:\/\/doi.org\/10.1093\/oncolo\/oyac050 (2022).","journal-title":"Oncologist"},{"issue":"9","key":"6113_CR13","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1634\/theoncologist.2019-0744","volume":"25","author":"D De Melo Gagliato","year":"2020","unstructured":"De Melo Gagliato, D. et al. Impact of delayed neoadjuvant systemic chemotherapy on overall survival among patients with breast Cancer. Oncologist 25 (9), 749\u2013757 (2020).","journal-title":"Oncologist"},{"issue":"5","key":"6113_CR14","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1213\/ANE.0000000000005398","volume":"132","author":"P Schober","year":"2021","unstructured":"Schober, P. & Vetter, T. R. Count data in medical research: Poisson regression and negative binomial regression. Anesth. Analgesia. 132, (5), 1378\u20131379 (2021).","journal-title":"Anesth. Analgesia"},{"issue":"2","key":"6113_CR15","doi-asserted-by":"publisher","first-page":"2100354","DOI":"10.1002\/bimj.202100354","volume":"65","author":"V Deltuvaite-Thomas","year":"2023","unstructured":"Deltuvaite-Thomas, V. et al. Generalized pairwise comparisons for censored data: an overview. Biom. J. 65 (2), 2100354 (2023).","journal-title":"Biom. J."},{"key":"6113_CR16","unstructured":"R CORE TEAM. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2023. Available at: https:\/\/www.R-project.org\/"},{"issue":"7","key":"6113_CR17","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1634\/theoncologist.2018-0535","volume":"24","author":"DS O\u2019neil","year":"2019","unstructured":"O\u2019neil, D. S. et al. Neoadjuvant chemotherapy use for nonmetastatic breast Cancer at five public South African hospitals and impact on time to initial Cancer therapy. Oncologist 24 (7), 933\u2013944 (2019). Epub 2018 Dec 5.","journal-title":"Oncologist"},{"key":"6113_CR18","doi-asserted-by":"crossref","unstructured":"Siegel, R. L., Miller, K. D., Jemal, A. & Cancer statistics. CA Cancer J Clin. 68(1), 7\u201330. https:\/\/doi.org\/10.3322\/caac.21442. Epub 2018 Jan 4. (2018).","DOI":"10.3322\/caac.21442"},{"issue":"2","key":"6113_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10549-023-07129-1","volume":"203","author":"A Schiza","year":"2024","unstructured":"Schiza, A., Fredriksson, I., Sund, M. & Valachis, A. Treatment utilization and effectiveness of neoadjuvant chemotherapy comparing men and women diagnosed with breast cancer: a Swedish retrospective cohort study. Breast Cancer Res. Treat. 203 (2), 235\u2013243 (2024).","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"6113_CR20","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1186\/s12885-016-2766-3","volume":"15","author":"A Hennigs","year":"2016","unstructured":"Hennigs, A. et al. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer. 15 (1), 734. https:\/\/doi.org\/10.1186\/s12885-016-2766-3 (2016).","journal-title":"BMC Cancer"},{"key":"6113_CR21","unstructured":"Inca, I. Nacional De C\u00e2ncer Jos\u00e9 Alencar Gomes Da Silva. A Situa\u00e7\u00e3o Do C\u00e2ncer De Mama No Brasil: S\u00edntese De Dados Dos Sistemas De Informa\u00e7\u00e3o (\/ Instituto Nacional de C\u00e2ncer Jos\u00e9 Alencar Gomes da Silva, 2019)."},{"issue":"9","key":"6113_CR22","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S1470-2045(20)30398-3","volume":"21","author":"SW Duffy","year":"2020","unstructured":"Duffy, S. W. et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK age trial): final results of a randomised, controlled trial. Lancet Oncol. 21 (9), 1165\u20131172 (2020). Epub 2020 Aug 12.","journal-title":"Lancet Oncol."},{"issue":"22","key":"6113_CR23","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1001\/jama.2024.5534","volume":"331","author":"US Preventive Services Task Force","year":"2024","unstructured":"US Preventive Services Task Force. Screening for breast cancer: US preventive services task force recommendation statement. JAMA 331 (22), 1918\u20131930 (2024).","journal-title":"JAMA"},{"key":"6113_CR24","doi-asserted-by":"crossref","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68 (6), 394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020;70(4):313. (2018).","DOI":"10.3322\/caac.21492"},{"key":"6113_CR25","unstructured":"Edge, S. B. et al. American Joint Committee on Cancer. AJCC Cancer Staging Manual 8th Ed. 8th ed., Springer, (2017)."},{"key":"6113_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s42047-022-00121-x","volume":"5","author":"H Gobbi","year":"2022","unstructured":"Gobbi, H. et al. Optimizing pathological assessment of breast cancer in brazil: recommendations from a multidisciplinary working group on the tumor-tissue journey. Surg. Exp. Pathol. 5, 20. https:\/\/doi.org\/10.1186\/s42047-022-00121-x (2022).","journal-title":"Surg. Exp. Pathol."},{"issue":"11","key":"6113_CR27","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","volume":"2","author":"LM Spring","year":"2016","unstructured":"Spring, L. M. et al. Neoadjuvant endocrine therapy for Estrogen Receptor-Positive breast cancer: A systematic review and Meta-analysis. JAMA Oncol. 2 (11), 1477\u20131486 (2016).","journal-title":"JAMA Oncol."},{"issue":"2","key":"6113_CR28","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10549-019-05397-4","volume":"178","author":"AC Pariser","year":"2019","unstructured":"Pariser, A. C. et al. Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the united States. Breast Cancer Res. Treat. 178 (2), 419\u2013426. https:\/\/doi.org\/10.1007\/s10549-019-05397-4 (2019). Epub 2019 Aug 10.","journal-title":"Breast Cancer Res. Treat."},{"key":"6113_CR29","doi-asserted-by":"crossref","unstructured":"Harbeck, N. et al. . Breast cancer. Nature Reviews Disease Primers. 5. https:\/\/doi.org\/10.1038\/s41572-019-0111-2 (2019).","DOI":"10.1038\/s41572-019-0111-2"},{"issue":"1","key":"6113_CR30","doi-asserted-by":"publisher","first-page":"R6","DOI":"10.1186\/bcr1639","volume":"9","author":"LK Dunnwald","year":"2007","unstructured":"Dunnwald, L. K., Rossing, M. A. & LI, C. I. Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res. 9 (1), R6 (2007).","journal-title":"Breast Cancer Res."},{"issue":"7","key":"6113_CR31","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1590\/1806-9282.20210249","volume":"67","author":"R Da Costa","year":"2021","unstructured":"Da Costa, R., Oliveira, F., Ara\u00fajo, A. & Vieira, S. C. Prognostic factors in triple-negative breast cancer: a retrospective cohort. Revista Da Associa\u00e7\u00e3o M\u00e9dica Brasileira. 67 (7), 950\u2013957. https:\/\/doi.org\/10.1590\/1806-9282.20210249 (2021).","journal-title":"Revista Da Associa\u00e7\u00e3o M\u00e9dica Brasileira"},{"key":"6113_CR32","doi-asserted-by":"crossref","unstructured":"Cabral, A.L.L.V., Giatti, L., Casale, C. & Cherchiglia, M. L. Social vulnerability and breast cancer: differentials in the interval between diagnosis and treatment of women with different sociodemographic profiles. Cien Saude Colet. 24 (2), 613\u2013622. https:\/\/doi.org\/10.1590\/1413-81232018242.31672016 (2019).","DOI":"10.1590\/1413-81232018242.31672016"},{"key":"6113_CR33","doi-asserted-by":"publisher","first-page":"927748","DOI":"10.3389\/fonc.2023.927748","volume":"13","author":"C Ferreira Ass","year":"2023","unstructured":"Ferreira, A. S. S. et al. Breast cancer survival and the health system in brazil: an analysis of public and private healthcare. Front. Oncol. 13, 927748 (2023).","journal-title":"Front. Oncol."},{"issue":"2","key":"6113_CR34","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.breast.2014.01.006","volume":"23","author":"CM Gonzaga","year":"2014","unstructured":"Gonzaga, C. M., Freitas-junior, R., Souza, M. R., Curado, M. P. & Freitas, N. M. Disparities in female breast cancer mortality rates between urban centers and rural areas of brazil: ecological time-series study. Breast 23 (2), 180\u2013187. https:\/\/doi.org\/10.1016\/j.breast.2014.01.006 (2014).","journal-title":"Breast"},{"issue":"1","key":"6113_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.4103\/ijmpo.ijmpo_21_18","volume":"40","author":"M Pathak","year":"2019","unstructured":"Pathak, M. et al. Role of neoadjuvant chemotherapy in breast cancer patients: systematic review and meta-Analysis. Indian J. Med. Pediatr. Oncol. 40 (1), 48\u201362. https:\/\/doi.org\/10.4103\/ijmpo.ijmpo_21_18 (2019).","journal-title":"Indian J. Med. Pediatr. Oncol."},{"key":"6113_CR36","doi-asserted-by":"crossref","unstructured":"Gianni, L. et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375 (9712), 377\u2013384. https:\/\/doi.org\/10.1016\/S0140-6736(09)61964-4 (2010).","DOI":"10.1016\/S0140-6736(09)61964-4"},{"key":"6113_CR37","doi-asserted-by":"crossref","unstructured":"Debiasi, M. et al. Estimated Number Of Breast Cancer Deaths In The Brazilian Public Health System Due To Lack Of Access To Adjuvant Trastuzumab Between 2005 And 2012. Jco 33, E17601-E17601 (2015).","DOI":"10.1200\/jco.2015.33.15_suppl.e17601"},{"key":"6113_CR38","doi-asserted-by":"crossref","unstructured":"Schmid, P. et al. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. N Engl J Med. 386 (6), 556\u2013567 (2022).","DOI":"10.1056\/NEJMoa2112651"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06113-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06113-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06113-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T15:15:16Z","timestamp":1751382916000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06113-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6113"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06113-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"19 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20907"}}